[Glucose tolerance on long-term treatment with a progestogen (etynodiol diacetate) (author's transl)].
Continuous long-term treatments with progestogens are able to bring about an hyperinsulinic reaction, which up till now has been considered to be due to a peripheral anti-insulin effect. Isolating the levels of immuno-reactive plasma insulin and of human C-peptide at the same time when loads of glucose and of tolbutamide are given after one another would seem to demonstrate that there is a primitive beta-islet of Langerhans origin for this hyperinsulinaemia. These results show that it is safe to prescribe etynodiol diacetate to "normal" patients as well as to "diabetic" patients.
D000328:Adult; D002096:C-Peptide / Q000097:blood; D005040:Ethynodiol Diacetate / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005947:Glucose / Q000378:metabolism*; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood*; D013997:Time Factors; D014044:Tolbutamide; D014591:Uterine Diseases / Q000188:drug therapy
D002096:C-Peptide; D007328:Insulin; D005040:Ethynodiol Diacetate; D014044:Tolbutamide; D005947:Glucose
Glycorégulation et traitement progestatif au long cours (diacétate d'etynodiol).